Raising the Bar in ATTR Amyloidosis

Program Description

There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the treatment armamentarium. Even with pharmacotherapeutic advances, however, the need to accurately diagnose patients remains vital. Increased disease awareness, early recognition of signs/symptoms, and appropriate diagnostic testing are essential to the timely initiation of treatment and the ultimate goal of optimizing patient quality of life and long-term prognosis. The CME Circuit Training™ platform provides an engaging, self-directed educational experience that not only addresses these topics but prepares clinicians to effect positive changes in ATTR amyloidosis care.

Target Audience

This activity is designed to educate neurologists and cardiologists, as well as a secondary audience of specialty physicians involved in the multidisciplinary management of patients with transthyretin-mediated amyloidosis (ATTR), including but not limited to primary care practitioners (PCPs), gastroenterologists, and rheumatologists..

Educational Objectives

1. Explain the underlying pathophysiology of ATTR amyloidosis, both hereditary and wild type.
2. Describe the constellation of symptom manifestations of ATTR amyloidosis, including genotype-phenotype correlates.
3. Screen patients when a high suspicion of ATTR amyloidosis is present and confirm that proper diagnostic testing is administered.
4. Review clinical trial data and future directions for disease-modifying therapies for ATTR amyloidosis.
5. Recommend disease-modifying therapies and/or symptom management for ATTR amyloidosis, ensuring proper monitoring and follow-up.

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Julian D. Gillmore, MD, PhD Consulting fees: Alnylam, AstraZeneca, Attralus, Inc., BridgeBio, Intellia; Speakers bureaus: Alnylam, AstraZeneca

Sami L. Khella, MD Consulting fees: Alnylam, AstraZeneca, Ionis, Medscape, Pfizer

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.